BioSpace News Archive

Deals

Alumis Pushes Through With Smaller IPO, Looks to Raise $250M for Immuno Candidate

Alumis is debuting in an initial public offering Friday on the Nasdaq, though the $250 million IPO is less than its initial targeted raise of $274 million just days ago.

June 28, 2024
·
2 min read
·
Tristan Manalac
Policy

FDA Rejects Rocket’s Gene Therapy, Cites Need for Additional CMC Info

Rocket Pharmaceuticals’ gene therapy Kresladi has been hit with an FDA Complete Response Letter requesting additional chemistry, manufacturing and controls information to complete its review.

June 28, 2024
·
2 min read
·
Tyler Patchen
Drug Development

Gilead’s Trodelvy Stumbles in Late-Stage Trials But Remains Prized Cancer Asset

Gilead Sciences’ blockbuster antibody-drug conjugate Trodelvy has encountered some clinical speed bumps in 2024 in bladder and lung cancer. Still, analysts remain bullish on its prospects in the oncology space.

June 28, 2024
·
4 min read
·
Tyler Patchen
Drug Development

Beyond GLP-1s: The Next Obesity Treatments

Eli Lilly, Rivus Pharmaceuticals and more target different biological processes in hopes of generating higher-quality weight loss and avoiding metabolic issues.

June 28, 2024
·
6 min read
·
Heather McKenzie